Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer-Reference-Cited by-同舟云学术

Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer

Published:2024-03 Issue:2 Volume:15 Page:101705
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Stevens Samuel,Nindra Udit,Shahnam Adel,Wei Joe,Bray Victoria,Pal Abhijit,Yip Po Yee,Linton Anthony,Blinman Prunella,Nagrial Adnan,Lee Jenny,Boyer Michael,Kao Steven

Funder

National Health and Medical Research Council

Publisher

Elsevier BV

Reference34 articles.

1. Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (SEER) database;Navada;J Clin Oncol,2006

2. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system;Chen;Cancer.,2014

3. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007;Walters;Thorax.,2013

4. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

5. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Spigel;J Clin Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer;Frontiers in Oncology;2024-07-16